Status:
COMPLETED
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
Lead Sponsor:
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Heart Failure, Congestive
Renal Insufficiency
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
Eligibility Criteria
Inclusion
- Stable congestive heart failure
- Impaired renal function
- Taking oral loop diuretic
Exclusion
- Acutely decompensated (unstable) and end stage heart failure
- Diuretics other than loop diuretics
- Pregnant or nursing
- Inability to follow instructions
- Participation in another clinical trial within past 30 days
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00159614
Start Date
September 1 2005
Last Update
January 29 2008
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
San Diego, California, United States
2
Baltimore, Maryland, United States
3
Ayer, Massachusetts, United States
4
Boston, Massachusetts, United States